Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation.
about
Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactionsProtein aggregation and its impact on product qualityHigh-throughput analysis of concentration-dependent antibody self-association.Role of anisotropic interactions for proteins and patchy nanoparticles.Do clustering monoclonal antibody solutions really have a concentration dependence of viscosity?Concentration Dependent Ion-Protein Interaction Patterns Underlying Protein Oligomerization BehavioursSmall-angle neutron scattering characterization of monoclonal antibody conformations and interactions at high concentrations.The limitations of an exclusively colloidal view of protein solution hydrodynamics and rheology.High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.A multiscale view of therapeutic protein aggregation: a colloid science perspective.High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.A versatile noninvasive method for adsorber quantification in batch and column chromatography based on the ionic capacity.High concentration biotherapeutic formulation and ultrafiltration: Part 1 pressure limits.Effects of Histidine and Sucrose on the Biophysical Properties of a Monoclonal Antibody.Liquid-liquid phase separation of a monoclonal antibody and nonmonotonic influence of Hofmeister anions.From osmotic second virial coefficient (B22 ) to phase behavior of a monoclonal antibody.Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches.Control of protein particle formation during ultrafiltration/diafiltration through interfacial protection.Characterization of highly concentrated antibody solution - A toolbox for the description of protein long-term solution stabilityComputational tool for the early screening of monoclonal antibodies for their viscositiesWeak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameterMetal ion interactions with mAbs: Part 1.Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies.Effects of ionic strength and sugars on the aggregation propensity of monoclonal antibodies: influence of colloidal and conformational stabilities.Use of CE-SDS gel for characterization of monoclonal antibody hinge region clipping due to copper and high pH stress.The osmotic pressure of highly concentrated monoclonal antibody solutions: effect of solution conditions.Investigation of Color in a Fusion Protein Using Advanced Analytical Techniques: Delineating Contributions from Oxidation Products and Process Related Impurities.Viscosity Analysis of Dual Variable Domain Immunoglobulin Protein Solutions: Role of Size, Electroviscous Effect and Protein-Protein Interactions.Quantitative Correlation between Viscosity of Concentrated MAb Solutions and Particle Size Parameters Obtained from Small-Angle X-ray Scattering.Viscosity measurement based on the tapping-induced free vibration of sessile droplets using MEMS-based piezoresistive cantilevers.Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy.Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process.
P2860
Q27002558-86B57A40-A3D2-4E61-898E-A3F4AEF93B7EQ27010661-B5D68348-147C-4B9A-BBB5-7D081D0AE8A5Q30462680-7CE1212F-C729-41C9-B5B5-B7DB9F0A0692Q34481834-058BDD7F-6B30-4481-AAD9-0565241B9E79Q36621942-A481EA68-2C43-4115-803D-B71E9B6E5D09Q36774473-0DA3B5B2-E7E8-403F-A84A-13481B19B2B6Q37078347-C2BD600E-5260-4F41-A423-E1FEFEC2C945Q37338052-73DECF00-FE9F-4583-ACCC-24280C63D797Q37469381-C18DE54E-EB4E-4B10-976B-27F291934823Q38378651-668DE56F-1025-4099-86FD-7835C531199FQ38718094-B19513BB-AB00-454B-A048-68FDD7F473EEQ38850558-AD5CB4D2-3B85-4345-A5D8-5EBBD4CC7A98Q38906930-8ED3A058-981F-4A35-A68C-38BDCD64F032Q39051343-1B72D95F-28B0-4ADD-BC97-53A300490619Q41152457-2D1662F4-5E20-4C65-A8A8-65F2DBA359BEQ41433310-844A7D2D-F2AF-424E-9688-BA1AA21C31A1Q41718661-D619119D-7C28-4A95-B5A5-3B8B91C6F349Q42009419-467D6D9B-B0D1-4499-8577-924D5415736EQ42111378-30A0E941-E180-44B8-A511-5992501F0389Q42117019-86D04922-4811-47E9-8FE9-56F9B89963BAQ42154434-23C4D9D7-DCC7-4B14-800F-D824726BB317Q43199899-356EA374-4E7A-4072-97D1-04B82C854768Q44528218-3876A63C-C15F-4813-9A96-0AFA6714AE00Q44588569-2A2D60C4-9D87-4583-8B7E-3914B1CA3757Q45853019-ACCDD273-9FC0-4E24-AACC-6BFA793D6B06Q46082056-8EE52631-83AB-4ADB-A653-C33346B02DB8Q46624990-EB97121C-E26E-4708-98A8-FF69E199C691Q47367882-80FC010F-570E-4859-9E70-520324AACC0CQ47380764-34D11438-5EDF-49DA-810B-6D8A37341058Q51486299-A01B7801-381E-4CAF-AD21-0829D92862FBQ51722272-4B7778ED-F5FC-4645-9935-C5BD36AF02D6Q53636388-3A9A4175-4BFB-40A4-AA44-028A3F185CE9
P2860
Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Understanding and modulating o ...... noclonal antibody formulation.
@en
type
label
Understanding and modulating o ...... noclonal antibody formulation.
@en
prefLabel
Understanding and modulating o ...... noclonal antibody formulation.
@en
P2093
P2860
P356
P1476
Understanding and modulating o ...... noclonal antibody formulation.
@en
P2093
Branden A Salinas
Hasige A Sathish
John F Carpenter
Steven M Bishop
P2860
P356
10.1002/JPS.21797
P407
P577
2010-01-01T00:00:00Z